Trevi Therapeutics Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, which engages within the growth and commercialization Haduvio to deal with critical neurologically mediated circumstances. It contains remedy of power pruritus related to prurigo nodularis and power cough in sufferers with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in sufferers with Parkinson’s illness. The corporate was based by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.